Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000 Apr;84(4):408-12.
doi: 10.1136/bjo.84.4.408.

Both CD4+ and CD8+ T cells are involved in protection against HSV-1 induced corneal scarring

Affiliations

Both CD4+ and CD8+ T cells are involved in protection against HSV-1 induced corneal scarring

H Ghiasi et al. Br J Ophthalmol. 2000 Apr.

Abstract

Aim: To determine the relative impact of CD4+ T cells and CD8+ T cells in protecting mice against ocular HSV-1 challenge.

Methods: CD4+ T cell knockout mice (CD4-/- mice), CD8+ T cell knockout mice (CD8-/- mice), and mice depleted for CD4+ or CD8+ T cells by antibody (CD4+ depleted and CD8+ depleted mice), were examined for their ability to withstand HSV-1 ocular challenge. The parental mice for both knockout mice were C57BL/6J.

Results: These results suggest that: (1) both CD4+ deficient mice (CD4-/- and CD4+ depleted mice) and CD8+ deficient mice (CD8-/-, and CD8+ depleted mice) developed significantly more corneal scarring than their C57BL/6J parental strain; (2) the duration of virus clearance from the eyes of the CD4+ deficient mice was 4 days longer than that of the CD8+ deficient mice; and (3) the severity of corneal scarring in the CD4+ deficient mice was approximately twice that of the CD8+ deficient mice.

Conclusions: It was reported here that: (1) CD4+ and CD8+ T cells were both involved in protection against lethal ocular HSV-1 infection; and (2) CD4+ and CD8+ T cells were both involved in protection against HSV-1 induced corneal scarring.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Survival of T cell deficient mice. Mice were inoculated ocularly with 2×106 pfu of McKrae as described in Materials and method. Survival was measured 28 days after ocular challenge. (A) Survival of CD8−/− and CD8+ depleted mice compared with C57BL/6J control mice after ocular infection with HSV-1. CD8−/− mice (n=10), CD8+ depleted (n=9), and C57BL/6J (n=9). (B) Survival of CD4−/− and CD4+ depleted mice compared with C57BL/6J control mice after ocular infection with HSV-1. CD4−/− mice (n=14), CD4+ depleted (n=9), and C57BL/6J (n=10).
Figure 2
Figure 2
Corneal scarring in T cell deficient mice. Corneal scarring was measured 28 days after ocular challenge as described in Materials and method in the mice shown in Figure 1 that survived ocular challenge. (A) Corneal scarring in CD8+ deficient mice; (B) corneal scarring in CD4+ deficient mice. For each bar, the corneal scarring (y axis) represents the average from 16 eyes (CD8−/− mice), 14 eyes (CD8+ depleted mice), 20 eyes (C57BL/6 mice), 16 eyes (CD4−/− mice), 18 eyes (CD4+ depleted mice), and 20 eyes (C57BL/6 mice) (SEM). *Similar to each other and significantly different from other groups (p<0.001, Student's t test).
Figure 3
Figure 3
Cytofluorimetric analysis of spleen cells from T cell deficient mice. (A) Spleens from two CD4−/− mice (solid bars) or two C57BL/6 mice depleted for CD4+ T cells with antibody (open bars) were harvested. Single cell suspensions of splenocytes were prepared, reacted with mAbs to CD4+ T cells (L3T4 mAb) and CD8+ T cells (Lyt-2 mAb) and FACS analysis was performed as described in Materials and methods. The level of CD4+CD8− T cells (CD4+) and the level of CD4−CD8+ T cells (CD8+) are shown relative to the level of these cells in untreated control C57BL/6 mice (horizontal line at 100%). Each bar represents the mean from two to four FACS analyses. (B) Spleen cells from two CD8−/− mice (solid bars) or two C57BL/6 mice depleted for CD8+ T cells with antibody (open bars) were prepared and FACS analysis performed as in (A).

References

    1. Immunity. 1996 Apr;4(4):337-47 - PubMed
    1. Invest Ophthalmol Vis Sci. 1995 Jun;36(7):1352-60 - PubMed
    1. Invest Ophthalmol Vis Sci. 1997 May;38(6):1213-21 - PubMed
    1. Immunology. 1997 Jul;91(3):430-5 - PubMed
    1. Curr Eye Res. 1997 Nov;16(11):1152-8 - PubMed

Publication types